M Pharmaceutical Inc (MPHMF) Rating Lowered to Sell at Zacks Investment Research
M Pharmaceutical Inc (NASDAQ:MPHMF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “M Pharmaceutical Inc. develops and commercializes biomedical technologies for treatment of obesity, diabetes and other gastroenterological indications primarily in Canada. The Company’s technology consists of Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; Trimtec, gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach and eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics. M Pharmaceutical Inc. is headquartered in Vancouver, Canada. “
Shares of M Pharmaceutical (NASDAQ:MPHMF) opened at 0.07 on Tuesday. M Pharmaceutical has a 52-week low of $0.01 and a 52-week high of $0.12. The stock’s market cap is $6.26 million. The company’s 50-day moving average price is $0.00 and its 200-day moving average price is $0.00.
M Pharmaceutical Company Profile
M Pharmaceutical Inc, formerly First Sahara Energy Inc, is a biomedical technology company. The Company is engaged in developing and commercializing drug treatments and biomedical technologies for the treatment of obesity and weight loss. The Company’s biomedical technologies include Trimeo, Trimtec and eMosquito.
Receive News & Stock Ratings for M Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for M Pharmaceutical Inc and related stocks with our FREE daily email newsletter.